Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/qjmed/hcae096 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Concomitant medication effects on patients with lung cancer taking immune checkpoint inhibitors a review.
Med Oncol
January 2025
Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, No. 55, Section 4, South Renmin Road, Chengdu, Sichuan, China.
In the past decade, a variety of immune checkpoint inhibitors (ICIs) are currently approved for lung cancer in the world. As a new therapeutic approach, ICIs have shown significant clinical benefits in the first-line or second-line treatment for advanced lung cancer, improving the survival and quality of life of patients. Patients need to take multiple drugs in the meantime due to their own disease or side effects during treatment.
View Article and Find Full Text PDFInfluence of Regular Statin Intake on Prostate-Specific Antigen Values, Prostate Cancer Incidence and Overall Survival in a Prospective Screening Trial (ERSPC Aarau).
Cancer Med
January 2025
Department of Urology, Cantonal Hospital Aarau, Aarau, Switzerland.
Article Synopsis
- The study investigated the impact of statin use on prostate cancer (PCa) development and prostate-specific antigen (PSA) levels in a cohort of 4,314 men over nearly 10 years.
- Statin users (761 men) had significantly lower baseline and follow-up PSA levels compared to non-users, but the overall incidence of PCa was similar between the two groups, indicating statins did not reduce the risk of developing PCa.
- Additionally, statin users had a higher risk of overall mortality, suggesting that while they had lower PSA levels, statin use did not confer a protective effect against prostate cancer.
Exploration of Novel Metabolic Features Reflecting Statin Sensitivity in Lung Cancer Cells.
Biol Pharm Bull
December 2024
Department of Veterinary Anatomy, School of Veterinary Medicine, Tottori University.
Article Synopsis
- Statins are drugs that lower cholesterol and have anti-cancer effects by inhibiting a key enzyme in cholesterol production.
- Research shows that the effectiveness of statins varies in different cancer cells, potentially linked to the presence of E-cadherin, which may act as a marker for statin sensitivity.
- Comparing gene expressions and metabolite levels in lung cancer cell lines revealed that statin-sensitive cells have lower cholesterol synthesis gene expression and reduced levels of related metabolites, indicating that these cells might have a limited capacity for cholesterol production and storage when treated with atorvastatin.
Characterizing the genetic architecture of drug response using gene-context interaction methods.
Cell Genom
December 2024
Bioinformatics Interdepartmental Program, University of California Los Angeles, Los Angeles, CA 90095, USA; Department of Neurology, University of California Los Angeles, Los Angeles, CA 90095, USA; Department of Computational Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA; Department of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA. Electronic address:
Identifying factors that affect treatment response is a central objective of clinical research, yet the role of common genetic variation remains largely unknown. Here, we develop a framework to study the genetic architecture of response to commonly prescribed drugs in large biobanks. We quantify treatment response heritability for statins, metformin, warfarin, and methotrexate in the UK Biobank.
View Article and Find Full Text PDFSynergistic antitumor effects of atorvastatin and chemotherapies: In vitro and in vivo studies.
Biochem Biophys Res Commun
January 2025
Research Lab. of Molecular Carcinogenesis, Zoology Department, Faculty of Science, Tanta University, Tanta, 31527, Egypt.
Atorvastatin (ATOR) acts on certain antitumor pathways; the consequences of chemotherapies continue to be a major concern, notwithstanding the increased efficacy provided by contemporary therapies. This study investigated the synergistic effects and underlying mechanisms of different treatment protocols using ATOR on the THP-1 cell line and on lung cancer in mice. For the in vitro study, an MTT assay was performed, and then different combinations against the THP-1 cell line were used as follows: non-treated cells, THP-1/ATOR IC, THP-1/cytarabine (CYT) IC, THP-1/doxorubicin (DOX) IC, THP-1/DOX/CYT, THP-1/ATOR/CYT, THP-1/ATOR/DOX, and THP-1/ATOR/CYT/DOX.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!